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acteristics, treatments, symptoms, seizure frequency and severity as well as com-
plete Patient Reported Outcomes (PRO) instruments (e.g. QOLIE-31/P, HADS). Uni-
variate and multivariate logistic regressions were performed to identify variables
associated with poor HRQoL (Quartile 1 of the QOLIE-31/P total score). RESULTS:
By May 2011, of the 2658 patients who had recorded a diagnosis of epilepsy and
multiple seizures, 1025 completed a PRO assessment and were included in this
analysis (mean age 37.5 years; 72.7% female; mean epilepsy duration from first
diagnosis 17.5 years). Median Q1-Q3 QOLIE-31/P total score was 50.5 (37.1-65.2),
with 256 patients being classifiedwith poor HRQoL. Multivariate logistic regression
indicated that poor HRQoL was more likely in patients reporting (Odds Ratio [95%
Confidence Interval]): 1)moderate/severe problems concentrating (3.19 [2.00-5.08]),
depression (2.61 [1.77-3.85]), memory problems (2.04 [1.29-3.24]), fatigue (1.75 [1.12-
2.71]), anxiety (1.49 [1.00-2.22]); 2) severe side effects (2.34 [1.39-3.92]); 3) at least one
tonic-clonic seizure during the 4 weeks before QOLIE-31/P completion (2.72 [1.65-
4.50]); 4) age 25-50 years (1.77 [1.01-3.11] vs. age 0-25 years); and 5) shorter epilepsy
duration (1 year 2.25 [1.23-4.13]; 1-10 years 1.70 [1.12-2.58]; both vs. 10 years).
Patients on polytherapy with newer antiepileptic drugs (AEDs) were less likely to
report poor HRQoL than patients on polytherapy with older AEDs (0.29 [0.11-0.74]).
CONCLUSIONS: These analyses indicate that moderate/severe problems concen-
trating, depression, the occurrence of generalized tonic-clonic seizures and of se-
vere side effects were the most predictive factors of poor HRQoL in the Patients-
LikeMe EpilepsyCommunity. These results suggest that a holistic approach beyond
seizure control should be considered when treating people with epilepsy.
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PATIENT-REPORTED BURDEN OF WALKING IMPAIRMENT IN MULTIPLE
SCLEROSIS
Sidovar M1, Horowicz-Mehler N2, Hawryluk EA2, Mccarthy S1
1Acorda Therapeutics, Inc., Hawthorne, NY, USA, 2Quintiles Global Consulting, Hawthorne, NY,
USA
OBJECTIVES:Walking impairment (WI) is a disabling hallmark ofmultiple sclerosis
(MS). This patient-centric study aimed to assess the clinical, psychological, and
economic burden of WI. METHODS: This cross-sectional study compared MS pa-
tients with (test group: TG, PDDS0) and without (control group: CG,PDDS0). WI
as assessed by the Patient Determined Disease Steps (PDDS) questionnaire.
PDDS3 describes patients with mild WI while PDDS4 reflects patients using a
walking device. Using validated patient-reported outcomes instruments, falls, de-
pression (Center for Epidemiologic Studies Depression Scale) resource utilization,
and work productivity (Work Productivity and Activity Impairment Questionnaire)
were assessed. Chi-square and t-test provided statistical significance to p0.01.
RESULTS: 346 adult MS patients around 11 years post-diagnosis participated. WI
was significantly different across groups (TG:PDDS3.2vs.CG:PDDS0). In the TG,
patients with WI using a device reported more healthcare visits for WI than pa-
tients with mild WI (PDDS4:58%vs.PDDS3:13%). TG patients reported “falling
sometimes” significantly more than CG patients (PDDS3:62%; PDDS4:50% vs.
PDDS0:14%). Compared to CG patients, more PDDS3 TG patients reported visit-
ing the hospital/ER (11% vs. 5%) or doctor’s office (16%vs.5%) for falls. WI requiring
the use of a device (PDDS4) increased the reportedhealthcare visits (32%:hospital/
ER;27%:doctor’s visits). TG patients reported depression significantlymore than CG
patients and 40% of these TG patients explicitly linked depression to WI. Absen-
teeism (10%vs.5%) and impairmentwhile working (35%vs.18%)were reportedmore
often in TG compared to CG patients. CONCLUSIONS: In this sample, WI was as-
sociated with increased falls, health care utilization, depression and lesser work
productivity. WI requiring use of a device appears to increase these effects. WI
effects could not fully be isolated from cognitive impairment and other effects, and
confounding by indication could affect estimates. Multivariate model research is
needed to validate these results in a broader population and quantify associated
costs.
PND39
WHAT IS THE INFLUENCE ON CLINICAL RESEARCH OF THE EMA GUIDELINE ON
MEDICINAL PRODUCTS FOR THE TREATMENT OF ALZHEIMER’S DISEASE?
Caron M, Acquadro C, Emery MP
MAPI Research Trust, Lyon, France
OBJECTIVES: In 2009, the EMA published a guideline onmedicinal products for the
treatment of Alzheimer’s disease. The guideline stipulates that symptoms im-
provement should be assessed in cognition (cognitive endpoint), activities of daily
living (functional endpoint) and overall clinical response (global endpoint). The two
primary endpoints should reflect the cognitive and functional domains. Global
assessment should be evaluated as a secondary endpoint. The objective of this
study is to review all products authorized by the EMA for the treatment of Alzhei-
mer’s before and after the publication of the guidance to see if the guidance had
any influence on clinical research or is only making existing practices official.
METHODS: The EMA website was searched with the keyword “Alzheimer” (EPAR
section, Keyword search). All EPARs and Scientific Discussions corresponding to
Alzheimer’s medicines were downloaded and reviewed. RESULTS: Ten products
were retrieved representing only two active substances: rivastigmine (8), and me-
mantine hydrochloride (2). Fourmedicineswere approved before the publication of
the guidance, and six afterwards (all generics of rivastigmine). The review of the
rivastigmine documents shows that the same studies were used for all products,
and that primary endpoints were cognitive and global; functional was secondary.
The review of the memantime documents shows that the same studies were used
for all products. For two studies, the EMA advised the sponsors that primary end-
points should be functional and global; cognitive was secondary. For two other
studies, global and cognitive measures were primary endpoints; functional was
secondary.CONCLUSIONS: Before 2009, symptoms improvement is assessed in the
three recommended domains. The primary and secondary endpoints, however,
were not always consistent with those advised by the guideline, and sometimes
contradicted them. The review cannot show any influence of the guidance on
clinical research since all products approved after its publication are generics of
rivastigmine.
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OBJECTIVES: Tomake an assessment of cognitive abilities of caregivers of individ-
uals with Alzheimer’s disease and to determine the risk of developing dementia in
this population. METHODS: A cross-sectional research design, utilizing a conve-
nience sample and one-on-one interviews, was adopted to address the study ob-
jectives. Family caregivers were recruited from New York City caregiver support
groups. Cognitive Abilities Screening Instrument (CASI), a pre-validated cognitive
scale, was used to assess the risk of dementia among the caregivers and a demo-
graphically similar sample of non-caregivers. CASI tests nine cognitive domains,
and a score of  74 on a scale between 1 and 100 indicates possible cognitive
impairment. The component scores of CASI were utilized to derive Mini Mental
State Examination (MMSE-CE) scores. Both MMSE-CE and individual component
scores of CASI were compared for the caregiver and non-caregiver groups.
RESULTS: The final data set consisted of 51 caregivers and 62 non-caregivers. Sig-
nificant differences were observed between the two with respect to CASI score (t
-2.311, p 0.001), MMSE-CE score (t -1.943, p 0.013) and individual domain
scores. Prevalence and number of medical conditions seemed to affect caregivers’
cognitive performance more than the non caregivers. Further, age and duration of
caregiving were revealed to be significant predictors of dementia risk in the care-
giver population based on both binary logistic (OR10.706, P 0.027,) andmultiple
linear regression (-0.306, P 0.028) models. CONCLUSIONS: This study provides
insights regarding the impact of caregiving on Alzheimer’s caregivers, specifically
with respect to their cognitive functioning. There is a greater likelihood of family
caregivers experiencing cognitive decline, significantly raising their risk of devel-
oping dementia sometime in the future. Health interventions should be designed
to make caregivers aware of the risks they face if they neglect their own health in
the process of caregiving.
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OBJECTIVES: To assess whether combined surgery and best medical therapy re-
sulted in better outcomes than best medical therapy alone, in patients with ad-
vanced Parkinson’s disease (PD).METHODS: The PD SURG trial is an ongoing ran-
domised, open-label trial. At 13 neurosurgical centres in the UK, between
November 2000, and December 2006, patients with PD (that was not adequately
controlled bymedical therapy) were assigned to either, combined surgery and best
medical therapy, or to best medical therapy alone. The primary endpoint was the
quality of life PRO measure, the 39-item Parkinson’s disease questionnaire (PDQ-
39). Changes between baseline and 1 year were compared by use of t tests.
RESULTS: 366 patients were randomly assigned to receive immediate surgery and
bestmedical therapy (183) or bestmedical therapy alone (183). All patientswhohad
surgery had deep brain stimulation. At 1 year, the mean improvement in PDQ-39
summary index score compared with baseline was 5.0 points in the surgery group
and 0·3 points in the medical therapy group (difference –4·7, 95% CI –7·6 to –1·8;
p0.001); the difference in mean change in PDQ-39 score in the mobility domain
between the surgery group and the best medical therapy group was –8·9 (95% CI
–13·8 to –4·0; p0.0004), in the activities of daily living domain was –12·4 (–17·3 to
–7·5; p0.0001), and in the bodily discomfort domain was –7·5 (–12·6 to –2·4;
p0.004). Differences between groups in all other domains of the PDQ-39 were not
significant. Other serious adverse events will be reported. CONCLUSIONS: At one
year, surgery and best medical therapy improved patient self-reported quality of
life more than best medical therapy alone in patients with advanced Parkinson’s
disease. These differences are clinicallymeaningful, but surgery is not without risk
and targeting of patients most likely to benefit might be warranted.
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OBJECTIVES: Alzheimer’s disease (AD) is the most common type of dementia for
which there is no cure. In a world where lifespan is increasing, dementia is becom-
ing more evident. In 2010, approximately 35.6 million people were living with de-
mentia and this number is likely to increase to 115.4 million in 2050. This study is
aimed to assess co-morbidity, quality of life (QOL), work/productivity loss, and
medical resource utilization in caregivers of AD in Brazil. METHODS: A total of
12,000 individuals’ (age 18) self-reported data were collected from 2011 National
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